文献速递消化系统肿瘤

局部错配修复缺陷型结直肠癌的新辅助免疫检查点抑制剂治疗:综述

Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer: A Review.
PubMed 文献 · JAMA Oncol · 2023-01-01

本文综述局部dMMR结直肠癌新辅助免疫检查点抑制剂(ICI)治疗的前景。多项2期研究显示完全临床和病理缓解率达60%-100%,3级及以上ICI相关毒性低。中位随访12至25个月,需更长期随访确认缓解持久性及肿瘤学结局不被损害。

要点

  • 局部dMMR结直肠癌新辅助ICI的完全临床和病理缓解率为60%-100%。
  • 3级及以上ICI相关毒性反应发生率低。
  • 中位随访12至25个月,需更长期随访确认缓解持久性和肿瘤学结局。

核心结论

  • 本综述发现局部dMMR结直肠癌新辅助免疫治疗早期结果显示主要和完全病理缓解率高,但需更长期随访数据以确保肿瘤学结局不被损害并理想地得到改善。
  • 局部dMMR结直肠癌新辅助ICI治疗代表一种可能范式转变,对器官保留有启示。

研究设计与样本

  • 综述,汇总多项前瞻性2期研究,研究对象为有限数量的局部dMMR结直肠癌患者。

主要发现

  • 多项前瞻性2期研究显示局部dMMR结直肠癌新辅助ICI的完全临床和病理缓解率为60%-100%,3级及以上ICI相关毒性反应发生率低。
  • 这些研究中位随访为12至25个月,需更长期监测以确定缓解持久性并确保接受非手术治疗患者的肿瘤学结局不被损害。
  • 鉴于盆腔放疗和全直肠系膜切除术伴随的显著并发症,新辅助ICI治疗对直肠癌患者尤其有吸引力。
  • 正在进行和计划中的前瞻性2期试验将提供关于最佳新辅助治疗时长、ICI单药对比联合治疗以及辅助ICI治疗必要性等重要问题的进一步数据。

关键数值与推荐

  • 局部dMMR结直肠癌新辅助ICI的完全临床和病理缓解率为60%-100%。
  • 中位随访为12至25个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些研究中位随访为12至25个月,需更长期监测以确定缓解持久性并确保接受非手术治疗患者的肿瘤学结局不被损害。
  • 需更长期随访数据以确保肿瘤学结局不被损害并理想地得到改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Colorectal cancers (CRCs) with deficient DNA mismatch repair (dMMR) account for 15% of all CRCs. Deficient MMR is a predictive biomarker associated with responsiveness to immune checkpoint inhibitors (ICIs) in solid tumors, including CRC. The remarkable effectiveness of ICIs in metastatic CRC has led to their evaluation in the neoadjuvant and adjuvant treatment of localized disease. OBSERVATIONS: Multiple prospective phase 2 studies in limited numbers of patients with localized dMMR CRC demonstrate high complete clinical and pathological response rates (60%-100%) to neoadjuvant ICIs, with low rates of grade 3 or higher ICI-related toxic effects. Given the median follow-up of 12 to 25 months in these studies, longer-term monitoring is needed to determine the durability of response and to ensure that oncologic outcomes are not compromised in patients undergoing nonoperative management. Neoadjuvant ICI therapy is especially attractive for patients with rectal cancer given the significant morbidity that accompanies pelvic irradiation and total mesorectal excision. Ongoing and planned prospective phase 2 trials will provide further data on important issues, including optimal neoadjuvant treatment duration, ICI monotherapy vs combination, and the need for adjuvant ICI therapy. CONCLUSIONS AND RELEVANCE: While this review found that early results of neoadjuvant immunotherapy for localized dMMR CRC show high rates of major and complete pathological response, longer-term follow-up data are needed to ensure that oncologic outcomes are not compromised and are ideally improved. Neoadjuvant ICI therapy in localized dMMR CRC represents a potential paradigm shift with implications for organ preservation.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Emiloju OE, Sinicrope FA. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer: A Review. JAMA Oncol. 2023. PMID: 37676680. doi:10.1001/jamaoncol.2023.3323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。